Alpha Healthcare Acquisition Corp III - Unit

Alpha Healthcare Acquisition Corp. III operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 21, 2021 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Carmell Corp. is a regenerative medicine biotech company, which focuses on leveraging its core platform technology plasmabased bioactive material to stimulate tissue repair or growth after severe injury, disease or aging. Its products include Bone Healing Accelerant and Tissue Healing Accelerant. The company is headquartered in Pittsburgh, PA.

NEW YORK & PITTSBURGH--( BUSINESS WIRE )--Alpha Healthcare Acquisition Corp. III (Nasdaq: ALPA) (“ALPA”), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the execution of a definitive business combination agreement with Carmell Therapeutics Corporation (“Carmell™”), a Phase 2-stage biotechnology platform company developing allogeneic plasma-based biomaterials for bone and soft tissue healing indications.

Alpha Healthcare Acquisition Corp. III Announces Merger with Carmell Therapeutics, a Phase 2 Stage Biotechnology Platform Company Developing Allogeneic Plasma-based Biomaterials for Bone and Soft Tissue Healing Indications

New York, NY, July 26, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. III (the “Company”) announced today that it priced its initial public offering of 15,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Capital Market (“Nasdaq”) and will begin trading on, July 27, 2021, under the ticker symbol “ALPAU”. Each unit consists of one share of the Company's Class A common stock and one-fourth of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. Only whole warrants will be exercisable and will trade on the Nasdaq.  Once the securities comprising the units begin separate trading, shares of the Class A common stock and warrants are expected to be listed on Nasdaq under the symbols “ALPA” and “ALPAW,” respectively.

Alpha Healthcare Acquisition Corp. III Announces Pricing of $150 Million Initial Public Offering

News for Alpha Healthcare Acquisition Corp III - Unit Stock (ALPAU)